Efficacy and Safety of CRx-102 in Hand Osteoarthritis
Author Information
Author(s): Kvien T K, Fjeld E, Slatkowsky-Christensen B, Nichols M, Zhang Y, Prøven A, Mikkelsen K, Palm Ø, Borisy A A, Lessem J
Primary Institution: Diakonhjemmet Hospital, Oslo, Norway
Hypothesis
The study aimed to evaluate the efficacy and safety of CRx-102 compared to placebo in patients with hand osteoarthritis.
Conclusion
CRx-102 demonstrated efficacy by statistically reducing pain compared to placebo in hand osteoarthritis and was generally well tolerated.
Supporting Evidence
- CRx-102 was statistically superior to placebo at 42 days for changes in AUSCAN pain.
- The most frequently reported adverse event during the study was headache.
- 93% of the participants were females, indicating a female predominance in the study population.
- The study showed a significant reduction in joint pain VAS scores for CRx-102 compared to placebo.
Takeaway
This study tested a new medicine called CRx-102 to help people with hand pain from arthritis, and it worked better than a fake pill.
Methodology
The study was a blinded, randomised, placebo-controlled trial conducted at four centres in Norway over a 6-week period.
Potential Biases
The study was funded by the producer of CRx-102, which may introduce bias.
Limitations
The study had a high withdrawal rate due to headaches, which may limit the interpretation of the results.
Participant Demographics
The mean age of participants was 60 years, with 93% being females.
Statistical Information
P-Value
0.020
Confidence Interval
1.6 to 18.7
Statistical Significance
p=0.020
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website